International Clinical Trial: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD107 in Healthy Subjects

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120343) titled 'A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD107 in Healthy Subjects' on March 12.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Beijing Tiantan Hospital Affiliated to Capital Medical University

Condition: Prevention or treatment of arterial and venous thrombosis

Intervention: Group 1-15mg:SRSD107 15 mg (n=6) or matching placebo (n=2), single subcutaneous injection. Group 2-45mg:SRSD107 45 mg (n=6) or matching placebo (n=2), sing...